| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 18,110 | 26,420 | 24,880 | 20,780 | 16,380 |
| Sales Growth | -31.45% | +6.19% | +19.73% | +26.86% | +39.40% |
| Net Income | -7,170 | -8,470 | -2,150 | -2,790 | -7,480 |
| Net Income Growth | +15.35% | -293.95% | +22.94% | +62.70% | +11.48% |
Diadexus Inc (DDXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
DiaDexus, Inc. operates as a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The Company's patented product PLAC Test for Lp-PLA2, identifies hidden risk for heart attack and stroke. The PLAC Test is the only blood test cleared by the FDA to assess risk for coronary heart disease and ischemic stroke associated with atherosclerosis. DiaDexus, Inc. is headquartered in San Francisco, California.